Most people meet the word peptide on a product page. In Tempe, Arizona, one of the best-known uses of peptides involves nobody swallowing, injecting or applying anything. Researchers at Arizona State University’s Biodesign Institute printed thousands of random peptides onto glass slides and used them as bait for antibodies in a droplet of blood. The peptides were the measuring instrument, not the treatment. That distinction is worth carrying into every peptide claim a reader meets, and this story is a clean way to see it.
Ten thousand peptides on a glass slide
The technology is called immunosignaturing, and it grew out of ASU’s Center for Innovations in Medicine, directed by Stephen Albert Johnston, with Phillip Stafford among the researchers behind it. Its core is a microarray: a glass slide printed with thousands of tiny spots, each holding a different short peptide. In the chip described in a Biodesign report, those were random-sequence chains 20 amino acids long, and a single chip carried 10,000 of them.
Random is the point. A conventional test goes looking for a known marker. This one does not. A droplet of blood, reported at under a microliter, is spread across the slide, and antibodies in the sample stick to some peptides more tightly than to others. The pattern of what sticks, read as a map across the chip, is the immunosignature. Different immune histories leave different patterns, much as different fingers leave different whorls.
Why a random chain can read a specific immune response
It sounds as if it should not work. Why would a peptide with no connection to any disease respond to a disease at all? The group’s own papers give the answer. In a 2014 BMC Cancer study of canine lymphoma, the authors explain that the peptides act as mimetics of real antibody targets and that the method relies on the cross-reactivity of antibodies. An antibody raised against one target will often bind weakly to several lookalikes. Even if the true target is not on the chip, some peptide on it resembles that target closely enough to catch the antibody.
Nobody needs to know in advance what the antibodies are aimed at. The chip records a pattern of partial matches, and software learns which patterns go with which conditions. In ASU news coverage, Johnston has described the longer-term aim as measuring each person against their own baseline immune activity instead of a population standard.
The unglamorous part: making the spots repeat
A reader could finish the story so far and decide the clever part is the random peptides. The papers suggest otherwise. In a study by the Biodesign group (Hughes, Cichacz, Scheck, Coons, Johnston and Stafford), the team repeated an experiment three years after the first, using the same peptide sequences. In between, they had changed how the chips were printed and how the slide surface was prepared. They report that the average variation between spots across an array, expressed as a coefficient of variation, fell from above 50 percent to below 15 percent.
That is a quality number, and it belongs to the same family as a purity figure on a vial. Ten thousand spots mean nothing if the chain in each one differs from batch to batch, or if the amount deposited wanders. A diagnostic built on peptides lives or dies on whether the right molecule is present, in a repeatable amount, every time. The peptide is the easy part to describe and the hard part to control.
From a campus laboratory to a company
Useful ideas at a university rarely stay there. In October 2020, Calviri, a company led by Johnston, announced that ASU’s technology transfer arm, Skysong Innovations, had granted it an exclusive license to ASU’s immunosignature patent portfolio. Calviri describes itself as a biotech startup focused on cancer, and it is a spinout of the Biodesign Institute. Later ASU work kept testing how far the method stretches. A 2023 ASU news release described immunosignatures recovered from dried blood spots that correlated strongly with those from fresh serum, and the team also assessed saliva.
What the Tempe example teaches about reading peptide claims
Put the immunosignature chip next to a cosmetic serum, a prescription medicine and a vial sold for laboratory work. All four contain peptides. The word is identical and the job is completely different. On the chip the peptide is a reagent. In the serum it is an ingredient. In the medicine it is an approved drug with a regulator’s record behind it. In the vial it is a research material with no approval for human use. A claim that does not say which of these it is talking about has not yet said anything.
Locally, educational pages such as those at Peptides Tempe aim to give readers that context, and the habit is worth copying. A good place to practice is a single compound. Copper peptides are a common example, because results from cell cultures and animal models are often quoted as if they described people. A short guide on how to read copper peptide studies shows what to check: which molecule was used, since a result for one compound does not automatically transfer to another, what was actually measured, and whether the model was cells, animals or humans. It also notes that human evidence is thinner and shorter-term than headlines suggest.
Four questions to ask of any peptide claim
- What job is the peptide doing here: reagent, ingredient, approved medicine or research material?
- Which exact molecule was tested, and is it the one being discussed? Names that sound alike can describe different sequences.
- Which model produced the result, cells, animals or people, and how many, for how long?
- What was measured? A shift in a laboratory marker and a change a person can feel are different results, and only the second answers most readers’ questions.
Add a date to all four. Regulatory status for several peptides moved more than once this year, so a status line with no date is a guess.
Where to look next
Readers in the Phoenix area have an unusual advantage, because the laboratory that built the immunosignature chip publishes in open journals and through ASU news. Start with those primary sources, then see how a local educational page frames the same science. The mission statement at peptidestempe.com says its aim is to explain what researchers are investigating, what human studies have found and where further research is needed. Hold any page to that standard, that one included.
